1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

SphingoTec GmbH

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2013

Location

Hennigsdorf Brandenburg Germany

Primary Industry

Biotechnology

About

Established in 2013 and based in Brandenburg, Germany, 4TEEN4 Pharmaceuticals GmbH, formerly known as Sphingotec Therapeutics GmbH, operates as a biopharmaceutical company that develops Procizumab, a humanized monoclonal antibody that helps for the treatment of cardiovascular diseases and other diseases related to massive cell death.
Current Investors
Wellington Partners, HBM Partners, NRW Bank

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.sphingotec.com/
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo